Last A$0.02 AUD
Change Today +0.001 / 6.67%
Volume 980.1K
As of 1:58 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/30/13 - A$0.03
52 Week Low
09/18/13 - A$0.0050
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMUGENE LTD (IMU)

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited, a pharmaceutical company, is engaged in the research, development, and commercialization of health technologies in Australia. The company’s drug delivery platform technology, Linguet enables the active ingredient of drugs to be absorbed into the bloodstream when placed inside the cheek or under the tongue for the treatment of Vitamin D deficiency, Parkinson’s disease, osteoporosis, and non-steroidal anti-inflammatory drugs. The company is also involved in the development of Vitamin D tablet for buccal delivery; and lead cancer vaccine product targeting gastric cancer and breast cancer. Imugene Limited is based in Armadale, Australia.

imugene ltd (IMU) Top Compensated Officers

Executive Director and Member of Audit Commit...
Total Annual Compensation: A$164.8K
Joint Company Secretary
Total Annual Compensation: A$124.8K
Company Secretary
Total Annual Compensation: A$12.0K
Compensation as of Fiscal Year 2014.

imugene ltd (IMU) Key Developments

Imugene Ltd. Auditor Raises 'Going Concern' Doubt

Imugene Ltd. filed its Annual on Aug 28, 2014 for the period ending Jun 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Imugene Ltd. Appoints Charles Walker as CEO

Imugene Ltd. appointed Charles Walker as Chief Executive Officer. Mr. Walker has experience across many aspects of the biotechnology and life sciences industry. His experience includes significant operational and leadership experience, a strong capital markets track record from executing nearly 50 international fundraisings both as principal and advisor, as well as a detailed scientific understanding gained from his technical background in pharmacology. Most recently, Charlie was CEO as well as former CFO of Alchemia Limited.

Mymetics Corporation and Imugene Partner to Develop Cancer Immunotherapy Vaccine Candidate

Mymetics Corporation has entered into an exclusive agreement with Imugene to manufacture and develop its cancer immunotherapy, HER-Vaxx, which is planned to enter into a PhaseI/II clinical trial in 2015. Mymetics will use its strong experience and specialist know-how in virosome based vaccines and integrating antigens in viral membranes to manufacture the Imugene HER-Vaxx cancer immunotherapy vaccine candidate.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMU:AU A$0.02 AUD +0.001

IMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.2x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 21.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMUGENE LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at